Farnesoid X receptor up-regulates expression of Lipid transfer inhibitor protein in liver cells and mice

Biochemical and Biophysical Research Communications

Volumn 441, Issue 4, 2013, Pages 880-885

  Li, Liangpeng ^a   Liu, Hong ^a   Peng, Jiahe ^a   Wang, Yongchao ^a   Zhang, Yan ^a   Dong, Jinyu ^a   Liu, Xiaohua ^a   Guo, Dongmei ^a   Jiang, Yu ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

ApoF; Apolipoprotein F; CETP; Chenodeoxycholic acid; Cholesterol ester transfer protein; FXR; High density lipoprotein; Low density lipoprotein

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; APOLIPOPROTEIN; APOLIPOPROTEIN F; BETA ACTIN; CHENODEOXYCHOLIC ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID TRANSPORT; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

MUS;

APOF; APOLIPOPROTEIN F; CETP; CHENODEOXYCHOLIC ACID; CHOLESTEROL ESTER TRANSFER PROTEIN; FARNESOID X RECEPTOR; FXR; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ANIMALS; APOLIPOPROTEINS; CHENODEOXYCHOLIC ACID; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; ISOXAZOLES; LIVER; MICE; MICE, INBRED C57BL; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; UP-REGULATION;

EID: 84888824428     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.10.156     Document Type: Article

References (24)

1. Izem L., Morton R.E. Molecular cloning of hamster lipid transfer inhibitor protein (apolipoprotein F) and regulation of its expression by hyperlipidemia. J. Lipid Res. 2009, 50:676-684.
2. Morton R.E., Greene D.J. Conversion of lipid transfer inhibitor protein (apolipoprotein F) to its active form depends on LDL composition. J. Lipid Res. 2011, 52:2262-2271.
3. Barter P.J., Brewer H.B., Chapman M.J., Hennekens C.H., Rader D.J., et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:160-167.
4. Shah P.K. Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease. Eur. Heart J. 2007, 28:5-12.
5. Kujiraoka T., Nakamoto T., Sugimura H., Iwasaki T., Ishihara M., et al. Clinical significance of plasma apolipoprotein F in Japanese healthy and hypertriglyceridemic subjects. J. Atheroscler. Thromb. 2013, 20:380-390.
6. Rizzo G., Renga B., Mencarelli A., Pellicciari R., Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2005, 5:289-303.
7. Bishop-Bailey D., Walsh D.T., Warner T.D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. USA 2004, 101:3668-3673.
8. He F., Li J., Mu Y., Kuruba R., Ma Z., et al. Downregulation of endothelin-1 by farnesoid X receptor in vascular endothelial cells. Circ. Res. 2006, 98:192-199.
9. Kast H.R., Nguyen C.M., Sinal C.J., Jones S.A., Laffitte B.A., et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol. Endocrinol. 2001, 15:1720-1728.
10. Zhang Y., Lee F.Y., Barrera G., Lee H., Vales C., et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. USA 2006, 103:1006-1011.
11. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009, 58:2711-2717.
12. Masson D. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis. Curr. Opin. Investig. Drugs 2009, 10:980-987.
13. Nicholls S.J., Brewer H.B., Kastelein J.J., Krueger K.A., Wang M.D., et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011, 306:2099-2109. .
14. Koren E., McConathy W.J., Alaupovic P. Isolation and characterization of simple and complex lipoproteins containing apolipoprotein F from human plasma. Biochemistry 1982, 21:5347-5351.
15. Hermann M., Ruschitzka F.T. The hypertension peril: lessons from CETP inhibitors. Curr. Hypertens. Rep. 2009, 11:76-80.
16. Paromov V.M., Morton R.E. Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J. Biol. Chem. 2003, 278:40859-40866.
17. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6:507-515.
18. Sinal C.J., Tohkin M., Miyata M., Ward J.M., Lambert G., et al. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000, 102:731-744.
19. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 2004, 113:1408-1418.
20. Pineda Torra I., Claudel T., Duval C., Kosykh V., Fruchart J.C., et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol. Endocrinol. 2003, 17:259-272.
21. Claudel T., Inoue Y., Barbier O., Duran-Sandoval D., Kosykh V., et al. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 2003, 125:544-555.
22. Mak P.A., Kast-Woelbern H.R., Anisfeld A.M., Edwards P.A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 2002, 43:2037-2041.
23. Hanniman E.A., Lambert G., McCarthy T.C., Sinal C.J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 2005, 46:2595-2604.
24. Urizar N.L., Dowhan D.H., Moore D.D. The farnesoid X-activated receptor mediates bile acid activation of phospholipid transfer protein gene expression. J. Biol. Chem. 2000, 275:39313-39317.